A comprehensive pathophysiology and pharmacology diagram illustrating the mechanisms by which Ashwagandha (Withania somnifera) influences human physical performance. The flowchart integrates predictive regulation models with biochemical pathways. At the top, 'Prior Knowledge' (comprising genetics, environment, developmental conditions, and demographics) leads to 'Optimized Adaptations,' which inform a 'Prediction' loop affecting 'Physical Performance' outcomes, including Strength & Power, Cardio-Respiratory Fitness, and Fatigue & Recovery. The biochemical section details the conversion of DHEA to Androstenedione via 3̢β-HSD, and the reversible conversion between Androstenedione and Testosterone via 17β-HSD. Ashwagandha components, specifically withanolides (Withaferin A, Withanoside IV, Withanolide A, Ashwagandhanolide, Withanone, and Sominone), are shown as primary mediators. These compounds influence neuroendocrine systems (decreasing cortisol, increasing testosterone) and immune responses (increasing antioxidant status, decreasing NF-κκB). These primary mediators cascade into secondary outcomes (inflammatory, cardiovascular, and metabolic efficiency) and tertiary outcomes (enhanced physical and mental health, sleep efficiency), which are monitored as biological sensors to provide feedback for predictive physical performance regulation.

A complex pathophysiology diagram and signaling pathway illustrating the mechanism of action for anti-inflammatory agents (drugs, natural, and synthetic compounds) on inflamed adipose tissue. The visual maps a cascade of intracellular and extracellular molecular players within a hypothetical adipocyte and surrounding immune environment. Key signaling nodes include the inhibition of TLR2/4, MyD88, and TRIF, alongside the activation of AMPK, GRP120, and SIRT-1. The diagram details the downregulation of pro-inflammatory pathways, specifically the NF-kβ complex and its downstream chemokines like MCP-1/CCL2. It also highlights the modulation of metabolic regulators such as PPAR-γ, SREBP1c, and UCP-1/2/3. In the lower section, the diagram shows the transition from a pro-inflammatory M1 macrophage phenotype (characterized by TNF-α, IL-6, and IL-1β) toward an anti-inflammatory M2 phenotype (indicated by IL-10, IL-13, and Arg1). The overall clinical outcomes depicted include reduced macrophage infiltration, decreased adipocyte hypertrophy, and improved insulin sensitivity markers such as GLUT-4 and IRS-1. Symbol legends indicate activation, inhibition, and phosphorylation states for each molecular player.

A medical infographic and signaling pathway diagram illustrating the dual mechanisms of Bruton’s tyrosine kinase inhibitors (BTKi) in the treatment of SARS-CoV-2. Section (a) details the 'Indirect mechanism' focused on antiviral effects. It depicts a SARS-CoV-2 virion with structural components (Membrane protein, SRBD, N protein) and nonstructural proteins (Nsp). It also shows host cell receptors ACE2 and TMPRSS2. A summary table outlines how BTKi may inhibit host attachment, viral replication, RNA translation, viral entry, and protein fusion by targeting these specific viral and host components. Section (b) illustrates the 'Direct mechanism' focusing on immunomodulatory effects via BTK signaling. It compares two states: 'with BTKi' and 'without BTKi'. Without inhibition, a pathologic state involves abnormal TLR7/8 and TLR3 signaling, leading to NF-kB and NLRP3 activation, resulting in a 'cytokine storm' (TNF-a, IL-6, IL-12, etc.). With BTKi, the pathway shifts to activate TLR3-mediated antiviral MAPK/AKT signaling while blocking NF-kB and NLRP3 pro-inflammatory pathways. This educational content demonstrates pharmacological strategies for drug repurposing in infectious disease and immunology.

A pathophysiology diagram illustrating the molecular mechanisms of curcumin in inhibiting the progression of Non-Alcoholic Fatty Liver Disease (NAFLD) to Liver Fibrosis (LF) and Hepatocellular Carcinoma (HCC). The top section shows three liver states: fatty liver, fibrotic liver, and cancerous liver, with arrows representing disease progression and inhibitory T-bars indicating curcumin's intervention. Below, a cellular cross-section details curcumin's interaction with transmembrane receptors and intracellular signaling pathways. Key regulatory cascades shown include the inhibition of NF-̄kB and its downstream inflammatory cytokines (TNF-́, IL-6, IL-1̂), and the TGF-̂/Smad pathway leading to ́-SMA and collagen production in activated Hepatic Stellate Cells (HSC). On the right, pathways involving ROS, AMPK, p53, and Bax/Bcl2 demonstrate the modulation of oxidative stress and the induction of apoptosis via Caspase 3. Additional signaled molecules include AKT, JNK, Nrf2, PPAR-́, and STAT3, collectively highlighting curcumin's multifaceted role in anti-inflammatory, anti-fibrotic, and anti-tumorigenic processes within hepatocytes.

A complex pathophysiology diagram and signaling pathway illustrating the mechanism of action for anti-inflammatory agents (drugs, natural, and synthetic compounds) on inflamed adipose tissue. The visual maps a cascade of intracellular and extracellular molecular players within a hypothetical adipocyte and surrounding immune environment. Key signaling nodes include the inhibition of TLR2/4, MyD88, and TRIF, alongside the activation of AMPK, GRP120, and SIRT-1. The diagram details the downregulation of pro-inflammatory pathways, specifically the NF-kβ complex and its downstream chemokines like MCP-1/CCL2. It also highlights the modulation of metabolic regulators such as PPAR-γ, SREBP1c, and UCP-1/2/3. In the lower section, the diagram shows the transition from a pro-inflammatory M1 macrophage phenotype (characterized by TNF-α, IL-6, and IL-1β) toward an anti-inflammatory M2 phenotype (indicated by IL-10, IL-13, and Arg1). The overall clinical outcomes depicted include reduced macrophage infiltration, decreased adipocyte hypertrophy, and improved insulin sensitivity markers such as GLUT-4 and IRS-1. Symbol legends indicate activation, inhibition, and phosphorylation states for each molecular player.

This pathophysiology diagram illustrates the inflammatory signaling pathway linking over-nutrition to metabolic disorders. The process begins with 'Over nutrition' (blue box), which acts upon adipose tissue (yellow lobular illustration) and the liver (brown anatomical representation). These tissues trigger macrophage activation, characterized by the signaling molecules NF-kB, P38, and JNK. The activated macrophages release pro-inflammatory cytokines TNF and IL-6. This inflammatory cascade leads to a clinical outcome box labeled 'Type 2 diabetes,' encompassing insulin resistance, fatty liver disease, and vascular disease. Additionally, the diagram features a therapeutic intervention point where 'curcumin' (red box) is shown with an inhibitory symbol (crossed circle) blocking the signaling pathway from the tissues to the macrophages. This content is relevant for endocrinology and metabolic health education, specifically demonstrating how nutritional excess promotes chronic systemic inflammation and secondary chronic diseases.